Adagio Medical Q2 2026: Cash Drops to $7.7M, Going Concern Warning, Nasdaq Delisting Risk
ADGM sits 94% above its 52-week low of $0.363 on light trading volume (0.2× avg).
Summary
Adagio Medical's Q2 2026 10-Q shows cash plummeting to $7.7M, a going concern warning with runway only into Q4 2026, and a Nasdaq delisting notice. The company is in a critical liquidity crisis with no revenue and mounting losses.
Key Events · Earnings and Guidance · ADGM
-
Going Concern Warning
Management states existing cash of $7.7M will fund operations only into Q4 2026, raising substantial doubt about the company's ability to continue as a going concern.
-
Cash Burn Accelerates
Cash dropped from $17.1M at year-end 2025 to $7.7M at June 30, 2026. Net loss widened to $6.7M in Q2 2026 vs $3.9M in Q2 2025, driven by higher R&D and non-cash convertible note fair value adjustments.
-
Nasdaq Delisting Notice
Received June 12, 2026, for failing to maintain a $1.00 minimum bid price. The company has until December 9, 2026, to regain compliance or face delisting.
-
Stockholders' Deficit
Total stockholders' equity swung to a deficit of $415K from $12.4M at year-end, driven by the accumulated deficit of $109.4M.
Analysis · ADGM · Industrial Applications And Services
Adagio Medical's Q2 2026 10-Q reveals a rapidly deteriorating financial position. Cash fell to $7.7 million from $17.1 million at year-end, and management now warns that existing funds will only last into the fourth quarter of 2026 — a sharp contraction from prior expectations. The company also disclosed a Nasdaq delisting notice received in June, adding listing compliance risk to the liquidity crisis. With no revenue, a $6.7 million quarterly net loss, and a stockholders' deficit, the company faces an urgent need for capital. The going concern warning and cash runway disclosure are new material facts that fundamentally alter the investment thesis.
At the time of this filing, ADGM was trading at $0.70 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $16.5M. The 52-week trading range was $0.36 to $2.58. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.